Experts say lax inspection and certification processes mean substandard products by repeat offenders are allowed to be sold in domestic and export markets
Up until October 5, New Delhi-headquartered Maiden Pharmaceuticals was having a relatively good run in the $25 billion pharmaceutical export market.
Maiden’s products were sold across the world, from Chile and Venezuela in the Latin American markets, to Senegal and Burkina Faso in Africa, and Vietnam and Cambodia in Southeast Asia. In all, according to the company’s website, its products are sold in over 41 countries.